An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Charles River Associates (CRA) Announces Vice President Promotions
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Charles River Associates (CRAI) has announced the promotion of six professionals to vice president roles within its consulting services. The newly appointed vice presidents include Sean Sheridan, Eddie Li, Erika Sloan, Griff Vinton, Uğur Akgün, and Vicki Mertzanidou. Each brings extensive expertise in their respective fields, such as Intellectual Property, Life Sciences, and Antitrust & Competition Economics. This strategic move is aimed at enhancing client service and fostering the company's growth and development. CRA's president, Paul Maleh, expressed pride in the achievements of the promoted leaders and their contributions to the firm.
Positive
Promotion of six vice presidents to enhance leadership and client service.
Increased expertise in Intellectual Property, Life Sciences, and Antitrust & Competition Economics.
Strategic positioning for future growth and development in consulting services.
“We are pleased to announce the promotions of these six talented leaders who not only excel in providing the depth of client service that distinguishes CRA, but also contribute to the growth of our firm and the professional development of our colleagues,” said CRA’s President and Chief Executive Officer Paul Maleh. “We appreciate their work and dedication to the firm and are proud to congratulate them on their achievements.”
“What truly distinguishes Sean Sheridan in the courtroom from other IP damages experts is his deep, real-world technology licensing experience with a broad range of technologies and collaborators, including research institutions, start-ups, and established companies,” said Daniel McGavock, Vice President and Intellectual Property Practice Leader.
“Our three new vice presidents in Life Sciences—Eddie Li, Erika Sloan, and Griff Vinton—are focused on data and the role that analytics can play in informing strategy across global life sciences industries, which is a testament to the opportunity that we see for big data in the life sciences,” said Dr. Gregory K. Bell, Vice President and Life Sciences Practice Leader.
"Our Antitrust & Competition Economics consultants, Uğur Akgün and Vicki Mertzanidou, continue to lead the way in developing innovative economic concepts and applying sophisticated economic analyses to global complex cases in merger review, antitrust, and litigation," said Margaret Sanderson, Vice President and Antitrust & Competition Economics Practice Leader. "Both based in London, they not only dominate in their respective fields and bring comprehensive and impactful analysis to their clients, but also have proven themselves to be strong leaders for our European colleagues."
Dr. Sean Sheridan joined CRA in 2014 and has served as an expert witness in cases brought before federal and state courts, the Patent Trial and Appeal Board, the International Trade Commission, and arbitration tribunals. Dr. Sheridan has developed numerous damages analyses related to patent infringement, breach of contract, and trade secret misappropriation, including analyses quantifying lost profits, reasonable royalties, and unjust enrichment. The engagements he has worked on span a wide range of industries and products, including pharmaceuticals, recombinant therapeutic proteins, vaccines, gene editing, medical devices, diagnostics, research tools, and electronic health records, as well as many others outside of the life sciences.
Eddie Li regularly leverages various data sources, including pharmacy and medical claims, affiliations, prescriptions, and sales/marketing data to inform commercial strategy. As Head of the Analytics Center of Excellence in the Life Sciences Practice, he provides guidance and oversight for internal R&D concerning machine-learning, cloud-based data platforms, and interactive data visualization. Mr. Li leads projects specializing in patient journey, patient finding, opportunity assessment, customer segmentation, and payer analytics.
Erika Sloan supports companies in the biopharma and healthcare diagnostics spaces from early-stage development through product launch and beyond. She leads projects that inform life sciences commercial strategy by integrating insights across different data sources including claims analytics, primary research, and secondary data, with an emphasis on strategic market research. Erika has extensive experience in global qualitative and quantitative research engagements, particularly buying process and patient journey analyses, customer segmentation and targeting, and opportunity assessments. Although her work spans a broad range of therapeutic areas, her particular fields of specialization are oncology and rare diseases.
Griff Vinton has more than 20 years of data-driven, client-service experience in a broad range of therapy areas and analytic investigational techniques, with a more recent focus and interest in neuro-psych disciplines, rare diseases, and patient record databases. He develops and delivers business intelligence solutions to support improved insight visualization and overall leverage of client investments in global information resources.
Dr. Uğur Akgün specializes in applying the most advanced economic theory in merger, abuse of dominance, and dispute cases. He has substantial experience designing and implementing a wide range of theoretical models that assist clients and regulators to understand the effects of mergers and regulatory actions. In addition to cases before the European Commission, the CMA, the UK Competition Appeals Tribunal, ICSID, and the WTO, Uğur has worked on cases in EU Member States and non-EU jurisdictions. His theoretical modeling expertise has been applied in numerous industries including aerospace, broadcasting and telecommunications, chemicals, mining, retailing, and technology.
Vicki Mertzanidou is an expert in competition economics with strong empirical skills. She has managed teams of economists in multiple large-scale empirical analyses in retail and other mergers. Vicki has advised clients in many of the most important merger cases before UK and European competition authorities. She has also worked on abuse of dominance, excessive pricing, and damages cases. Her experience spans a diverse range of industries from white fuels and chemicals to commercial retail property, pharmaceuticals, mobile towers, telecoms equipment, media data provision, betting, and many fast-growing consumer goods.
About Charles River Associates (CRA)
Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.
SAFE HARBOR STATEMENT
Statements in this press release concerning CRA’s Intellectual Property Practice, Life Sciences Practice, and the Antitrust & Competition Economics Practice, the expansion of these practices, and any future business CRA’s new vice presidents may generate for CRA, are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others: the failure to generate engagements for us; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition. Additional potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.
